This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

L'Oreal to Buy Up 8% Stake Held by Nestle

NEW YORK (The Deal) -- L'Oreal clearly thinks that it is worth it. The world's largest cosmetic's maker on Tuesday, Feb. 11, agreed to buy and cancel 8% of its stock owned by Nestle in exchange for 6.5 billion ($8.9 billion) in cash and assets, cutting the Swiss food company's stake to 23.3%.

L'Oreal will pay 3.4 billion in cash and transfer to Nestle the 50% it doesn't already own of Swiss dermatology company Galderma. The deal values L'Oreal's 50% stake in Galderma at 3.13 billion, including 490 million of debt.

The agreement ends immediate speculation that has surrounded Nestle's 29.4% stake in L'Oreal since August, when Nestle said it would let expire an option that gave L'Oreal's founding Bettencourt Meyers family a right of first refusal on the holding. That opened the door to a possible sale of the entire stake, prompting L'Oreal to declare that it had the means to buy the holding.

"It is a bit anticlimactic given all the speculation," said RBC Capital Markets' London-based analyst James Edward Jones. "It sounds as though Nestle is planning to stick around for the long-term."

Nestle considers its stake to be "strategic," Nestle Chairman Peter Brabeck-Letmathe told journalists on Tuesday. "I do not see this as the first step to leaving L'Oreal, not at all."

Nestle said it will continue to act in concert with the Bettencourt Meyers family, whose stake in L'Oreal will increase to 33.31%, from 30.6%, as a result of the cancellation of the shares by L'Oreal.

""I am very pleased with the proposed strategic transaction," L'Oreal Chairman and CEO Jean-Paul Agon said at a presentation of his company's annual results on Tuesday. "L'Oreal will benefit from the very significant stake of the family whose commitment to the company has always been total and will be further strengthened by this agreement."

The deal also secures L'Oreal's stake in French drug company Sanofi. L'Oreal owns 9% of Sanofi, a stake worth about 8.55 billion. It had been thought likely to sell the holding in the event that it bought all of Nestle's stake.

"We are a major shareholder in Sanofi and when we don't need to sell we don't sell," Agon told analysts.

The transaction values L'Oreal's shares at 124.48, a 3.5% discount to the Paris-based company's Monday closing price of 129 per share. The price represented a slim premium to L'Oreal's Friday closing price of 123.50, before reports emerged on Monday of an imminent deal.

The acquisition will boost earnings per share by more than 5% on a recurring basis, L'Oreal's Christian Mulliez, finance vice president, said Tuesday. The disposal of L'Oreal's 50% stake in Galderma comes just ahead of the implementation of new accounting rules that would have blocked it from consolidating the Galderma revenues in its accounts.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,085.41 -1.22 -0.01%
S&P 500 1,989.92 +2.91 0.15%
NASDAQ 4,478.7060 +5.0090 0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs